These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


874 related items for PubMed ID: 20015974

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy.
    Seyfarth HJ, Pankau H, Hammerschmidt S, Schauer J, Wirtz H, Winkler J.
    Chest; 2005 Aug; 128(2):709-13. PubMed ID: 16100158
    [Abstract] [Full Text] [Related]

  • 24. Long-term outcomes in pulmonary arterial hypertension in the first-line epoprostenol or first-line bosentan era.
    Jacobs W, Boonstra A, Brand M, Rosenberg DM, Schaaf B, Postmus PE, Vonk Noordegraaf A.
    J Heart Lung Transplant; 2010 Oct; 29(10):1150-8. PubMed ID: 20580264
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan.
    Benza RL, Rayburn BK, Tallaj JA, Pamboukian SV, Bourge RC.
    Chest; 2008 Jul; 134(1):139-45. PubMed ID: 18403673
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Efficacy of sildenafil as a rescue therapy for patients with severe pulmonary arterial hypertension and given long-term treatment with prostanoids: 2-year experience.
    Ruiz MJ, Escribano P, Delgado JF, Jiménez C, Tello R, Gómez MA, de la Calzada CS.
    J Heart Lung Transplant; 2006 Nov; 25(11):1353-7. PubMed ID: 17097500
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Long-term experience after transition from parenteral prostanoids to oral agents in patients with pulmonary hypertension.
    Diaz-Guzman E, Heresi GA, Dweik RA, Minai OA.
    Respir Med; 2008 May; 102(5):681-9. PubMed ID: 18280130
    [Abstract] [Full Text] [Related]

  • 35. Long-term outcome and effects of oral bosentan therapy in Taiwanese patients with advanced idiopathic pulmonary arterial hypertension.
    Hsu HH, Chen JS, Chen RJ, Ko WJ, Kuo SW, Wu ET, Wu MH, Wang JK, Lee YC.
    Respir Med; 2007 Jul; 101(7):1556-62. PubMed ID: 17223329
    [Abstract] [Full Text] [Related]

  • 36. Survival with first-line bosentan in patients with primary pulmonary hypertension.
    McLaughlin VV, Sitbon O, Badesch DB, Barst RJ, Black C, Galiè N, Rainisio M, Simonneau G, Rubin LJ.
    Eur Respir J; 2005 Feb; 25(2):244-9. PubMed ID: 15684287
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 44.